跳至主要内容
临床试验/NCT01853722
NCT01853722已完成2 期

A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers

Deacon Biosciences, Inc.1 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2013年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
62
试验地点
1
主要终点
Change from baseline in periocular region bacterial load

研究概览

简要总结

This proof-of-concept study evaluates the clinical efficacy and safety of DCN01 in prepping of the periocular region.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Have given a written, informed consent
  • Be willing and able to follow all instructions
  • A negative urine pregnancy test if female of childbearing potential

排除标准

  • Known sensitivities to study medication or its components
  • Any signs of an active infection
  • Use of disallowed products during the period indicated prior to the enrollment or during the study
  • Be currently pregnant, nursing, or planning a pregnancy; or be a woman that has a positive pregnancy test
  • Have a condition or a situation which, in the Investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation

研究组 & 干预措施

DCN01

Experimental

干预措施: DCN01 (Drug)

Unisol

Placebo Comparator

干预措施: Unisol (Drug)

结局指标

主要结局

Change from baseline in periocular region bacterial load

时间窗: Baseline to 10 min post dose

次要结局

  • Proportion of periocular regions with a reduction from baseline in bacterial load.(Baseline to 10 min post dose)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

A Phase 2, Open-Label, Randomized, Parallel Group,... | 临床试验